A New Paradigm in Drug Development - The mission of Bio-Path is to make its neutral lipid delivery the standard delivery technology for antisense therapeutics in the pharmaceutical industry.
Liposomal Grb-2 Clinical Trial

Bio-Path completed six cohorts of the Phase I clinical trial evaluating Liposomal Grb-2 in blood cancers. The drug’s safety profile continues to be favorable with no treatment-related serious adverse events reported and data suggests possible anti-leukemia activity. A maximum tolerated dose has yet to be reached. The clinical trial is being conducted at the MD Anderson Cancer Center.

Patients are currently being enrolled into a safety segment of a Phase II program evaluating Liposomal Grb-2 in combination with Ara-C for AML.

Latest News

Apr 7 2016 OncLive interview with Dr. Cortes on BP-100.01 in Patients with Relapsed/Refractory AML

Mar 23 2016Bio-Path Holdings Announces Research Collaboration on Autoimmune Indication with The University of Texas Southwestern Medical Center

Mar 15 2016Bio-Path Holdings Reports Fiscal Year 2015 Operational and Financial Results

Mar 8, 2016Bio-Path Holdings Announces Pancreatic Cancer Research Collaboration with Leading Oncology Institution

Mar 7, 2016Bio-Path Holdings to Present at the 28th Annual ROTH Conference on Monday March 14 at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time)

Mar 3, 2016Bio-Path Holdings Announces Completion of the Safety Segment of the Phase II Clinical Trial of BP1001 in Acute Myeloid Leukemia

Feb 1, 2016Bio-Path Holdings to Present at the 18th Annual BIO CEO & Investor Conference

Jan 26, 2016Bio-Path Hopes to Blaze Profitable Path With Antisense Drugs